Among well-investigated epigenetic drugs in the field of ovarian cancer are histone deacetyltransferase (HDAC) inhibitors, which work by increasing the level of acetylated histones thus reactivating silenced tumor suppressor genes. The gene discussed is HDAC9; the disease is ovarian cancer.